Olaratumab
Modify Date: 2024-07-28 17:17:51
Olaratumab structure
|
Common Name | Olaratumab | ||
|---|---|---|---|---|
| CAS Number | 1024603-93-7 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of OlaratumabOlaratumab (IMC-3G3; LY3012207) is an anti-platelet-derived growth factor receptor alpha (PDGFRα) human monoclonal IgG1 antibody with antitumor activity[1]. |
| Name | Olaratumab |
|---|
| Description | Olaratumab (IMC-3G3; LY3012207) is an anti-platelet-derived growth factor receptor alpha (PDGFRα) human monoclonal IgG1 antibody with antitumor activity[1]. |
|---|---|
| Related Catalog | |
| In Vitro | IMC-3G3 (100 μg/mL, 72 h) 阻断了SKOV3-ip1 细胞的 PDGFRα 磷酸化。并且 IMC-3G3 和多西他赛联合治疗时在 SKOV3-ip1 和 HeyA8 两种细胞系中显著诱导了凋亡[1]。 |
| In Vivo | IMC-3G3 (i.p., 40 mg/kg, three times per week, 6 weeks)在 SKOV3-ip1 荷瘤小鼠中，与对照组相比，IMC-3G3 单独处理没有明显的抗肿瘤作用，而在 HeyA8 荷瘤小鼠中，IMC-3G3 单药治疗与对照组相比显示出显著的抗肿瘤作用，肿瘤减少率为 62%[1]。 |
| References |
| No Any Chemical & Physical Properties |